Prognostic and biological significance of survivin expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapy

Zhiyu Liu, Zijun Y. Xu-Monette, Xin Cao, Ganiraju C. Manyam, Xiaoxiao Wang, Alexandar Tzankov, Yi Xia, Xin Li, Carlo Visco, Ruifang Sun, Li Zhang, Santiago Montes-Moreno, Karen Dybkær, April Chiu, Attilio Orazi, Youli Zu, Govind Bhagat, Kristy L. Richards, Eric D. Hsi, William W L ChoiJ. Han Van Krieken, Jooryung Huh, Maurilio Ponzoni, Andrés J M Ferreri, Ben M. Parsons, Michael B. Møller, Miguel A. Piris, Jane N. Winter, Dennis P. O'Malley, L. Jeffrey Medeiros, Ken H. Young

Research output: Contribution to journalArticle

Abstract

Survivin, a member of the inhibitor of apoptosis protein family, is overexpressed in a variety of human neoplasms. The prognostic significance of survivin expression in diffuse large B-cell lymphoma patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) is unclear. We used standard immunohistochemistry methods to quantify survivin expression in 463 patients with de novo diffuse large B-cell lymphoma who received the R-CHOP. Of the 463 patients, 269 (58%) had survivin overexpression with a cutoff of >25%, associated with an International Prognostic Index score of >2 (P=0.015), disease in ≥2 extranodal sites (P=0.011), and a high Ki-67 index (P

Original languageEnglish
Pages (from-to)1297-1314
Number of pages18
JournalModern Pathology
Volume28
Issue number10
DOIs
Publication statusPublished - Oct 3 2015

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Fingerprint Dive into the research topics of 'Prognostic and biological significance of survivin expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapy'. Together they form a unique fingerprint.

Cite this